The FDA hit Chinese drugmaker Shandong Vianor Biotech with a warning letter and placed the company on an import alert.

Amgen is expanding its cancer and inflammation biosimilar presence in China with a new deal with Simcere.

Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.

AstraZeneca rolled out positive results for a LAMA/LABA that could help the company gain a respiratory foothold in Asia.

Gilead Sciences has received approval for Sovaldi from China's FDA, gaining a foothold in the world's largest hepatitis C market.

Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.

South Korean drug manufacturer Firson was slapped with a warning letter and placed on an import alert by the FDA.

Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers

Pharma Asia